Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NVP-1402
- Development stage
- Phase 1
- Lead developer
- Navipharm
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
NVP-1402 is an orally administered investigational drug developed for central nervous system (CNS) disorders. It was initially developed by Navipharm and later advanced by NVP Healthcare. The drug has completed Phase 1 clinical trials in healthy male subjects, where its safety and pharmacokinetics were evaluated. Its precise mechanism of action has not been publicly disclosed, but it is being explored for potential use in nervous system diseases[1][2][3].
Beyond the preview
Go deeper on NVP-1402.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NVP-1402.